Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market

Benzinga

8 hours ago

Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood. The revised wholesale acquisition cost (WAC) will take effect on April 1. The drug is...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622898557"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622898557\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622898557?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/26/Konskie--Poland---ApIonis-Pharmaceutical.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-03-27 01:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622898557","market":"sh","top_or_hot":-1,"title":"Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market","media":"Benzinga","content":"<div>\n<p>Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.\nThe revised wholesale acquisition cost (WAC) will take effect on April 1. \nThe drug is...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/03/51491002/ionis-pharmaceuticals-repriced-drug-ahead-of-key-fda-decision-signals-push-into-larger-market\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIonis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-27 01:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/03/51491002/ionis-pharmaceuticals-repriced-drug-ahead-of-key-fda-decision-signals-push-into-larger-market><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.\nThe revised wholesale acquisition cost (WAC) will take effect on April 1. \nThe drug is...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/03/51491002/ionis-pharmaceuticals-repriced-drug-ahead-of-key-fda-decision-signals-push-into-larger-market\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/03/51491002/ionis-pharmaceuticals-repriced-drug-ahead-of-key-fda-decision-signals-push-into-larger-market","article_id":"2622898557","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/26/Konskie--Poland---ApIonis-Pharmaceutical.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/03/51491002/ionis-pharmaceuticals-repriced-drug-ahead-of-key-fda-decision-signals-push-into-larger-market","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622898557","pubTimestamp":1774547220,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Ionis Pharmaceuticals cuts Tryngolza price ahead of sHTG decision, with analysts seeing stronger sales potential and competitive positioning.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4148":"电子元件","IONS":"Ionis Pharmaceuticals, Inc","WAC":"Walter Investment Management","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","BK4518":"OLED概念","LPL":"LG Display Co ADS","BK4585":"ETF&股票定投概念"},"translate_title":"Ionis Pharmaceuticals在FDA关键决定信号进军更大市场之前重新定价药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"IONS":1.5,"LPL":1,"WAC":1},"content_text":"Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.\nThe revised wholesale acquisition cost (WAC) will take effect on April 1. \nThe drug is currently approved for familial chylomicronemia syndrome (FCS), but the pricing reset comes as Ionis prepares for a broader launch, with an FDA decision in sHTG expected by June 30.\nFCS is a rare, inherited metabolic disorder caused by lipoprotein lipase (LPL) enzyme deficiency, leading to extremely high triglyceride levels.\nIonis had previously guided to a significantly lower WAC range of $10,000 to $20,000 annually for sHTG.\nHowever, William Blair notes that the earlier-than-expected pricing adjustment reflects alignment with payer contracting cycles, as April 1 marks a key benchmark for commercial insurance budgeting.\nThe timing suggests Ionis is proactively positioning Tryngolza for formulary inclusion ahead of a potentially larger patient population.\nAnalyst Myles Minter described the pricing revision as a positive development as Ionis approaches a potential sHTG launch.\nAt $40,000 annually, the new price point is higher than prior guidance but aligns more closely with expectations based on clinical outcomes. Analysts note that Tryngolza's demonstrated impact on pancreatitis risk in the CORE studies supports a premium relative to earlier projections.\nThe pricing shift has prompted analysts to revisit their financial models. \nPrior assumptions were based on a net annual price of roughly $20,400, and updated forecasts are expected following Ionis' first-quarter earnings report, when management may provide product-specific guidance.\nThe revised pricing could drive upside to existing peak sales estimates. Previous projections exceeded $2 billion in sHTG, with some models reaching $2.6 billion based on 20% U.S. market penetration under the earlier pricing framework.\nAnalysts remain optimistic about regulatory approval by the June 30 PDUFA date. If approved, Tryngolza would enter a significantly larger market, transforming it into a wholly owned commercial opportunity for Ionis.\nThe combination of competitive pricing, strong clinical data, and broader indication potential positions the drug as a key near-term growth driver.\nWilliam Blair maintains the Outperform rating on Ionis.\nIONS Stock Price Activity: Ionis Pharmaceuticals shares were up 3.74% at $75.42 at the time of publication on Thursday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}